Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 19/20 | 0.68 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.58 |
| ▸ | KIT | P10721 | 5/20 | 0.51 |
| ▸ | SRC | P12931 | 5/20 | 0.51 |
| ▸ | FLT3 | P36888 | 5/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.51 |
| ▸ | INSR | P06213 | 2/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888669 | 0.93 | CSF1R (0.59) | CSF1RCAMK2DKITSRCFLT3 | |
| SCHEMBL4572878 | 0.91 | CSF1R (0.82) | CSF1RCAMK2DKITSRCFLT3 | |
| SCHEMBL4888300 | 0.90 | CSF1R (0.56) | CSF1RCAMK2DKITSRCFLT3 | |
| SCHEMBL4888723 | 0.87 | CSF1R (0.58) | CSF1RKITSRCFLT3NTRK1 | |
| SCHEMBL4888647 | 0.87 | CSF1R (0.77) | CSF1RKITSRCFLT3NTRK1 | |
| SCHEMBL4892188 | 0.85 | CSF1R (0.53) | CSF1RCAMK2DKITSRCFLT3 | |
| SCHEMBL4572794 | 0.85 | CSF1R (0.72) | CSF1RCAMK2DKITSRCFLT3 | |
| SCHEMBL4573128 | 0.84 | CSF1R (0.69) | CSF1RKITSRCFLT3NTRK1 | |
| SCHEMBL4888274 | 0.83 | CSF1R (0.68) | CSF1RKITSRCFLT3NTRK1 | |
| SCHEMBL4889583 | 0.82 | CSF1R (0.73) | CSF1RKITSRCFLT3NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080114007-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114007-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | FLT3, FES, ALK | CSF1R 430/4885CAMK2D 712/4885KIT 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.